New Entrant In Diabetes Market

April 2007 | Product Launch

BMI is restating the attractiveness of the Middle East region to pharmaceutical and biotechnology companies involved in the diabetes field after US-based Generex Biotechnology signed a licensing deal for its revolutionary insulin product. With many countries in the region demonstrating the highest prevalence of the disease in the world, this scenario should continue for some time. Indeed, after gaining first approval in the US or Western Europe, we strongly recommend producers of insulin products and diabetes diagnostics to introduce their offerings to the Middle Eastern markets immediately afterwards, given the inevitable swift uptake.

If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.